Table 4.
Associations between SMs and neuroinflammation biomarkers.
| sTREM2 (ng/mL) | IL6 (pg/mL) | YKL40 (ng/mL) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Metabolite | β | P | R2 | β | P | R2 | β | P | R2 |
| behenoyl SM (d18:1/22:0) | 0.47 | 0.03 | 0.11 | −0.02 | 0.48 | 0.03 | 6.87 | 0.05 | 0.31 |
| palmitoyl dihydro-SM (d18:0/16:0) | 1.64 | 5.15E-05 | 0.12 | 0.02 | 0.75 | 0.03 | 19.80 | 3.67E-03 | 0.32 |
| palmitoyl SM (d18:1/16:0) | 4.55 | 1.06E-16 | 0.17 | −0.10 | 0.12 | 0.03 | 63.27 | 2.92E-11 | 0.35 |
| SM (d18:1/14:0, d16:1/16:0) | 1.91 | 6.67E-07 | 0.12 | −0.07 | 0.18 | 0.03 | 27.02 | 5.14E-05 | 0.33 |
| SM (d18:1/18:1, d18:2/18:0) | 4.30 | 2.70E-14 | 0.17 | −0.17 | 7.56E-03 | 0.04 | 59.56 | 2.40E-09 | 0.35 |
| SM (d18:1/20:0, d16:1/22:0) | 1.48 | 7.69E-06 | 0.12 | −0.06 | 0.22 | 0.03 | 15.09 | 0.01 | 0.32 |
| SM (d18:1/20:1, d18:2/20:0) | 0.88 | 0.01 | 0.12 | −0.01 | 0.78 | 0.02 | 13.51 | 0.03 | 0.33 |
| SM (d18:1/22:1, d18:2/22:0, d16:1/24:1) | 1.03 | 9.70E-05 | 0.11 | −0.03 | 0.40 | 0.03 | 9.82 | 0.03 | 0.32 |
| SM (d18:1/24:1, d18:2/24:0) | 0.92 | 7.96E-04 | 0.12 | −0.03 | 0.44 | 0.03 | 5.99 | 0.19 | 0.32 |
| SM (d18:2/16:0, d18:1/16:1) | 2.26 | 1.12E-08 | 0.13 | −0.14 | 8.31E-03 | 0.04 | 31.62 | 3.08E-06 | 0.33 |
| SM (d18:2/24:1, d18:1/24:2) | 1.28 | 1.27E-05 | 0.12 | −0.05 | 0.23 | 0.03 | 11.71 | 0.02 | 0.32 |
| stearoyl SM (d18:1/18:0) | 6.99 | 3.15E-28 | 0.24 | −0.18 | 5.77E-03 | 0.04 | 105.64 | 1.41E-18 | 0.39 |
sTREM2: soluble triggering receptor found on myeloid cells 2; IL6: interleukin-6; YKL40: chitinase-3-like protein 1; β: change in the outcome with a one unit increase of the standardized metabolite level; P: P-value of the corresponding regression; R2: marginal R2 for the corresponding regression; bolded values indicate significant results at threshold p<3.47×10−4.